Conceptus, Inc.  

(Public, NASDAQ:CPTS)   Watch this stock  
Find more results for CPTS
30.97
-0.01 (-0.03%)
May 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.95 - 30.99
52 week 15.81 - 31.10
Open 30.95
Vol / Avg. 166,000.00/1.36M
Mkt cap 1.00B
P/E 109.06
Div/yield     -
EPS 0.28
Shares 32.43M
Beta 0.75
Inst. own 109%
Jul 29, 2013
Q2 2013 Conceptus Earnings Release Add to calendar
Mar 19, 2013
Conceptus at Roth Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 5.44% 3.82%
Operating margin 11.77% 9.49%
EBITD margin - 15.63%
Return on average assets 2.97% 2.12%
Return on average equity 4.23% 3.27%
Employees 286 -
Carbon Disclosure Rating - -

Address

331 East Evelyn Avenue
MOUNTAIN VIEW, CA 94041
United States - Map
+1-650-9624000 (Phone)
+1-650-9625200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Conceptus, Inc. designs, develops, markets and promotes solutions in women�s healthcare. The Company�s flagship product is the Essure permanent birth control procedure, which is the non-surgical permanent birth control system. The Essure delivers a soft and flexible insert into a woman�s fallopian tubes, causing a benign tissue in-growth, which blocks the fallopian tubes. Successfully placed Essure inserts and the subsequent tissue growth around, and through the inserts prohibits the egg from traveling through the fallopian tube, preventing conception. In October 2011, the Company acquired from its Dutch distributor certain assets and all distribution rights of the Essure device. In October 2011, it purchased certain assets of Sigma Medical and established a wholly owned subsidiary in the Netherlands, Conceptus B.V. (BV). During the year ended December 31, 2011, approximately 600,000 women worldwide have undergone the Essure procedure.

Officers and directors

Kathryn A. Tunstall Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
D. Keith Grossman President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Gregory E. Lichtwardt Chief Financial Officer, Treasurer
Bio & Compensation  - Reuters
Julie A. Brooks Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 66
Bio & Compensation  - Reuters
Lori M. Ciano Executive Vice President - Human Resources
Age: 49
Bio & Compensation  - Reuters
David Chung Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Feridun Ozdil Ph.D. Executive Vice President - Research and Development
Age: 48
Bio & Compensation  - Reuters
Joseph Sharpe Executive Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Peter L. Wilson Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
John L. Bishop Independent Director
Age: 68
Bio & Compensation  - Reuters